Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying the how well saracatinib works in treating patients with
metastatic or recurrent head and neck cancer. Saracatinib may stop the growth of tumor cells
by blocking some of the enzymes needed for cell growth